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Summary
 
Previous studies in murine models, including those using the 
 
b
 
2 microglobulin knockout
mouse, have suggested an important role for CD8
 
1
 
 T cells in host defense to 
 
Mycobacterium tu-
berculosis 
 
(Mtb). At present, little is understood about these cells in the human immune response
to tuberculosis. This report demonstrates the existence of human Mtb-reactive CD8
 
1
 
 T cells.
These cells are present preferentially in persons infected with Mtb and produce interferon 
 
g
 
 in
response to stimulation with Mtb-infected target cells. Recognition of Mtb-infected cells by
these CD8
 
1
 
 T cells is restricted neither by the major histocompatibility complex (MHC) class I
A, B, or C alleles nor by CD1, although it is inhibited by anti–MHC class I antibody. The
Mtb-specific CD8
 
1
 
 T cells recognize an antigen which is generated in the proteasome, but
which does not require transport through the Golgi-ER. The data suggest the possible use of
nonpolymorphic MHC class Ib antigen presenting structures other than CD1.
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I
 
t is estimated that a third of the world’s population is in-
fected with 
 
Mycobacterium tuberculosis
 
 (Mtb),
 
1
 
 the caus-
ative agent of tuberculosis. Consequently, tuberculosis is
the leading cause of infectious mortality worldwide, ac-
counting for over 8 million new cases and 2.9 million
deaths annually (1). Mtb is an intracellular pathogen and
thus the control of infection relies on the recognition and
destruction of infected cells.
There is abundant evidence to support an important role
for CD4
 
1
 
 T cell–mediated immunity in tuberculosis (2).
However, several lines of evidence also suggest a role for
CD8
 
1
 
 T cells in controlling Mtb infection. Mice deficient
in CD8
 
1
 
 T cells as a consequence of disruption of the gene
for 
 
b
 
2 microglobulin are more susceptible to Mtb infection
compared with their wild-type littermates (3). In addition,
mice in which the gene for CD8 has been disrupted are
also highly susceptible to Mtb infection (4). Recently, Silva
et al. found that CD8
 
1
 
 T cell clones generated to the Mtb
heat shock protein (hsp 65) could confer partial immunity
to Mtb infection in mice (5). Immunization of mice with
plasmids expressing hsp 65 (6), Ag 85a (7), or the 38-kD
(8) antigen resulted in the generation of antigen-specific
CD8
 
1
 
 CTLs that were associated with protection from
subsequent challenge with Mtb. Finally, Stenger et al.
demonstrated that human CD8
 
1
 
 CTLs restricted by CD1b
molecule are able to inhibit the growth of Mtb in vitro
 
 
 
(9)
 
.
 
In the host response to tuberculosis infection, CD8
 
1
 
 T
cells may exert a protective role via several mechanisms.
First, in response to antigenic stimulation, CD8
 
1
 
 T cells
produce cytokines such as IFN-
 
g
 
 and TNF-
 
a
 
. These cy-
tokines are potent macrophage activators and their impor-
tance has been illustrated by the increased susceptibility of
mice to Mtb challenge in which the genes for IFN-
 
g
 
 (10)
and TNF-R have been disrupted (11). Second, CD8
 
1
 
 T
cells may play a unique role in host defense to Mtb through
the release of granular constituents that promote the de-
struction of heavily infected macrophages and MHC class
II negative cells such as endothelial cells and fibroblasts.
The directed exocytosis of cytolytic granules by CD8
 
1
 
 T
cells induces apoptosis in the target cell. In this regard, it
has been suggested that apoptosis will kill intracellular my-
cobacteria (12). However, mice deficient in the expression
of perforin, granzyme, or CD95 (Fas) are still able to con-
 
1
 
Abbreviations used in this paper:
 
 DC, monocyte-derived dendritic cells;
ER, endoplasmic reticulum; FBS, fetal bovine serum; LCL, lymphoblastoid
cell line; Mtb, 
 
Mycobacterium tuberculosis
 
; PPD, purified protein derivative;
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tain infection with Mtb (13, 14), suggesting that in the
mouse model the secretion of macrophage-activating cy-
tokines such as IFN-
 
g
 
 and TNF-
 
a
 
 may be sufficient for
protective immunity. Alternatively, other components of
the cytotoxic granule may have a direct antimycobacterial
effect (9, 15).
The role of MHC class I–restricted CD8
 
1
 
 T cells in hu-
man immunity to tuberculosis remains largely unexplored.
Little is known about the mechanism by which Mtb anti-
gens might gain access to the MHC class I antigen-process-
ing pathway. Within the macrophage, Mtb resides prima-
rily in the phagosome (16, 17), a site thought inaccessible
to MHC class I processing. However, particulate antigens
have been shown to gain access to the MHC class I path-
way (18, 19), although the efficiency of these pathways re-
mains controversial (20).
This study demonstrates the existence of human Mtb re-
active CD8
 
1
 
 T cells. These cells are present preferentially
in persons infected with Mtb, and produce IFN-
 
g
 
 in re-
sponse to stimulation with Mtb-infected targets. Recogni-
tion of Mtb-infected cells by these T cells is not restricted
by either the MHC class I A, B, or C, alleles or by CD1,
although it is inhibited by anti–MHC class I antibody. We
demonstrate that the Mtb-specific CD8
 
1
 
 T cells recognize
an antigen that is generated in the proteasome, but which
does not require transport through the Golgi endoplasmic
reticulum (ER). The data suggest the possible use of non-
polymorphic MHC class Ib antigen-presenting structures
other than CD1.
 
Materials and Methods
 
Human Subjects.
 
Subjects were recruited from employees at
Harborview Medical Center, the Fred Hutchinson Cancer Re-
search Center, and the Corixa Corporation. Purified protein deriva-
tive of Mtb (PPD) responses were determined by the employee
health service at the respective institutions. Protocols for venipunc-
ture and apheresis were Institutional Review Board approved. HLA
typing was performed on PBL by the Puget Sound Blood Center.
 
Monoclonal Antibodies and Reagents.
 
Culture medium con-
sisted of RPMI-1640 supplemented with 10% fetal bovine serum
(FBS; BioWhittaker, Walkersville, MD), 50 
 
m
 
g/ml gentamycin
sulfate (BioWhittaker), 5 
 
3 
 
10
 
2
 
5 
 
M 2ME (Sigma Chemical Co.,
St. Louis, MO), and 2 mM glutamine (GIBCO BRL, Bethesda,
MD). For the generation of primary T cell lines and clones,
RPMI was supplemented with 10% human serum (HS). Mono-
clonal antibodies were generated from hybridoma supernatants
from the W6/32 and L243 cell lines obtained from American
Type Culture Collection (ATCC; Rockville, MD) using the
Affi-gel protein A MAPSII kit (Bio-Rad Laboratories, Hercules,
CA) according to the manufacturer’s instructions. 
 
M. tuberculosis
 
(H37Rv), 
 
Mycobacterium avium
 
, (ATCC 35718), and 
 
Mycobacte-
rium bovis 
 
(ATCC 35726) were grown in modified Middlebrook
7H9 media. After the preparation of glycerol stocks, aliquots
were frozen, and subsequently titered on Middlebrook 7H10
plates (Becton Dickinson Microbiology Systems; Cockeysville,
MD). 
 
E. coli 
 
LPS was obtained from Sigma. Infectious influenza
A/HK/68 was provided by Dr. Baldridge (RIBI ImmunoChem
Research Inc., Hamilton, MT).
 
Cell Lines and T Cell Clones.
 
EBV-transformed B cell lines
were generated in our laboratory using supernatants from the cell
line 9B5-8. Cell lines were maintained by continuous passage in
RPMI culture medium supplemented with 10% FBS. Clone
10D10-82, an HIV Gag-specific CD8
 
1
 
 T cell clone to the B44
restricted peptide 103 (AA 303-322; TLRAERASQDVKN-
WMTETLL) was provided by Dr. Stanley Riddell. Clone
D150M58-Cl6, an A2.1-restricted influenza matrix protein spe-
cific CD8
 
1
 
 CTL (AA 58-66; GILGFVFTL) was provided by Dr.
Steven Fling (Corixa Corporation).
 
Generation of Peripheral Blood Dendritic Cells.
 
Monocyte-derived
dendritic cells (DCs) were prepared according to Romani’s
method (21). In brief, PBMCs were isolated from heparinized
blood by centrifugation over Ficoll-Hypaque (Sigma Chemical
Co.) and washed three times with culture medium. Alternatively,
PBMCs were obtained via leukapheresis. Cells were resuspended
in RPMI containing 2% HS and allowed to adhere to a T-75 tis-
sue culture flask (Costar, Cambridge, MA) at 37
 
8
 
 for 1 h in the
presence of 10 ng/ml of GM-CSF (Immunex Corp., Seattle,
WA). After gentle rocking, nonadherent cells were removed, and
30 ml of RPMI/10% HS containing 10 ng/ml of IL-4 (Immunex
Corporation) and 30 ng/ml of GM-CSF (Immunex Corporation)
was added. After 18 h, the media was removed and centrifuged,
and the cell-conditioned media was placed on the adherent cells.
After 5–7 d, cells were harvested with cell-dissociation media
(Sigma Chemical Co.).
 
Flow Cytometry.
 
Cells to be analyzed for cell surface marker
expression were first incubated at 4
 
8
 
C in a blocking solution of
PBS containing 2% normal rabbit serum (Sigma Chemical Co.),
2% normal goat serum (Sigma Chemical Co.), and 2% HS to pre-
vent nonspecific binding of mouse Ig. Cells were washed in
FACS buffer (PBS containing 0.5% FBS and 0.02% sodium azide)
and incubated with either FITC-conjugated anti-TCR 
 
a/b
 
 or 
 
g/d
 
(T Cell Sciences, Needham, MA), anti-CD4, anti-CD8, anti-
CD14, anti-CD16, anti-CD56 antibodies (5 
 
m
 
g/ml) or an FITC-
IgG1 control (Becton Dickinson Immunocytometry Systems, San
Jose, CA; 5 
 
m
 
g/ml) for 30 min at 4
 
8
 
C in a total volume of 50 
 
m
 
l.
Cells were then washed, and flow cytometry was performed us-
ing a FACSCalibur
 
Ò
 
 (Becton Dickinson) and data were collected
on 10
 
4
 
 viable cells.
 
Generation of Mtb-reactive CD8
 
1
 
 T Cell Lines.
 
10
 
6
 
 monocyte-
derived DCs were cultured overnight in the presence of Mtb
(H37Rv; MOI 
 
5 
 
100) in low adherence 16-mm wells (Costar
No. 3473). After 18 h, the cells were harvested and resuspended
in RPMI/10% HS. These cells were cultured with 3 
 
3 
 
10
 
6
 
 T
cells depleted of CD4
 
1
 
 lymphocytes by adherence to immobi-
lized anti-CD4 (AIS MicroCELLector; Applied Immune Sci-
ences, Santa Clara, CA) and supplemented with IL-7 (10 ng/ml;
Immunex). T cells were re-stimulated with fresh, Mtb-infected
DCs on day 7. IL-2 (0.5 ng/ml; Chiron, Emeryville, CA) was
added on day 8 and every other day thereafter. T cells were posi-
tively selected on day 9, and cultured in the presence of IL-2. Af-
ter 2 d, cells were harvested, analyzed for the expression of CD4
and CD8 (94–98% CD8
 
1
 
; 
 
,
 
2% CD4
 
1
 
), and assessed for their
ability to generate IFN-
 
g
 
 in response to Mtb-infected cells. In
this assay, 2.5 
 
3 
 
10
 
5
 
 DCs were co-incubated with 10
 
6
 
 T cells in
16-mm wells (Costar). After 18–24 h, supernatants were har-
vested and an ELISA analysis was performed to determine the
concentration of IFN-
 
g
 
.
 
Generation of Mtb-reactive CD8
 
1
 
 T Cell Clones.
 
T cells were
cloned by limiting dilution in the presence of 2 
 
3 
 
10
 
5
 
 irradiated
(3,500 rads using a 
 
137
 
Cs source) heterologous PBMCs, 5 
 
3 
 
10
 
4
 
irradiated (7,000 rads) heterologous lymphoblastoid cell line
(LCL) cells, anti-CD3 (10 ng/ml), and recombinant IL-2 (10 
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ng/ml). Cell culture media consisted of 200 
 
m
 
l of RPMI supple-
mented with 10% HS. T cell clones were selected based upon the
generation of IFN-
 
g
 
 in response to Mtb-infected DCs.
Evaluation of the specificity of T cell clones for Mtb was per-
formed as follows: Mtb-infected DCs and control uninfected
DCs were prepared as above, and seeded at 3–5 
 
3 
 
10
 
4
 
 cells per
well in 96-well flat-bottomed plates (Costar) in 100 
 
m
 
l of RPMI/
10% HS. 5 
 
3 
 
10
 
4
 
 T cells were added in 100 
 
m
 
l of media, and su-
pernatants were harvested after 18–24 h for determination of
IFN-
 
g
 
. Assays were performed in the presence of 1.0 ng/ml IL-2.
 
Metabolic Inhibition of Antigen Presentation.
 
1 h before the ad-
dition of Mtb to DCs, lactacystin (40 
 
m
 
M; E.J. Corey, Harvard
Biolabs, Harvard, Cambridge, MA), brefeldin A (10 
 
m
 
g/ml;
Sigma Chemical Co.), chloroquine (100 mM; Sigma Chemical
Co.), or cytochalasin D (10 
 
m
 
g/ml; Sigma Chemical Co.) was
added to the culture medium. After 18 h of coincubation with
Mtb, cells were harvested and fixed in either 1% paraformalde-
hyde (Sigma Chemical Co.) or 0.1% glutaraldehyde (Grade I, 25%
aqueous; Sigma Chemical Co.). After vigorous washing, fixed DCs
were used as stimulators for CD8
 
1
 
 T cells as described above.
 
Results
 
Mtb-infected Monocyte-derived DCs Can Be Used To Elicit
CD8
 
1 T Cell Responses in Persons Infected with Mtb. Under
the influence of GM-CSF and IL-4, loosely adherent PBMCs
develop the membrane morphology and cell surface phe-
notype of DCs (21). Additionally, these cells have been
shown to be efficient in antigen presentation in both an
MHC class I– and class II–restricted manner (22). When
incubated overnight with live Mtb (H37Rv), these cells are
efficiently infected with intracellular bacilli as demonstrated
by transmission electron microscopy (data not shown).
To generate a recall CD81 T cell response to Mtb anti-
gens, DCs from a PPD positive, healthy individual were
coincubated with autologous CD8-enriched T cells. The T
cells were restimulated with fresh Mtb-infected DCs on
day 7, and were CD8-selected on day 10. On day 12, the
CD81 T cell line (96% by flow cytometry) was assessed for
its ability to recognize Mtb-infected autologous DCs. As
shown in Fig. 1, this CD81 T cell line produced IFN-g in
response to Mtb-infected DCs. IFN-g secretion was de-
pendent on the presence of both antigen (Mtb) and DCs.
To determine if the response seen represented a recall re-
sponse or in vitro priming, an identical protocol was per-
formed with an additional five PPD-positive, as well as six
PPD-negative individuals during three separate experi-
ments. As shown in Fig. 2, five out of five individuals with
evidence of exposure to Mtb generated CD81 T cell re-
sponses (stimulation index [SI] . 5). In contrast, four out of
six of those without evidence of exposure had no demon-
strable responses (SI, 2). Since none of the PPD-negative
donors were bacillus Calmette-Guérin–vaccinated, the two
responses that were observed may represent prior exposure
to nonpathogenic mycobacteria found in the environment.
Generation of Mtb-reactive CD81 T Cell Clones. CD81 T
cells were cloned by limiting dilution and individual clones
were selected for the ability to generate IFN-g in response
to Mtb-infected DCs. All of the CD81 Mtb-reactive
clones isolated were a/b TCR positive, and negative for
NK, B, and macrophage cell surface markers (data not
shown). As shown in Fig. 3, two such clones (23 and 29)
secreted IFN-g in response to Mtb-infected but not con-
trol DCs. LPS-treated DCs failed to stimulate the T cells.
As an additional control for the specificity of these T cells,
another CD81 T cell clone, 10D10-82, was assayed on the
same DC. Clone 10D10-82, an HIV Gag-reactive CD81
T cell clone, produced IFN-g when stimulated with the B44-
restricted Gag peptide 103 (AA 303-322; TLRAERA-
SQDVKNWMTETLL), but did not respond to Mtb-infected
DCs. In addition to Mtb, clone 23 responded strongly to
DCs infected with M. bovis, but minimally to DCs infected
with M. avium (Fig. 4). Taken together, these data demon-
strate that the CD81 T cell clones are specific for Mtb
complex mycobacteria.
Antigen Presentation Is Not Restricted to a Specific MHC A,
B, or C Allele. In an attempt to define a restricting MHC
class I allele for the Mtb-reactive CD81 T cell clones, a
panel of DCs was generated that matched the T cells at one
HLA-A, -B, or -C locus. Surprisingly, CD81 T cell clones
were able to generate IFN-g after incubation with the Mtb-
infected DCs from all of the donors, indicating that these
cells are not restricted by a single HLA-A, -B, or -C allele
(Fig. 5). Similarly, presentation to CD81 T cells by infected
DCs did not correlate with expression of any particular
HLA-DR or -DQ allele, and thus restriction by HLA-DR or
Figure 1. CD81 T cell line
produces IFN-g in response to
Mtb-infected DCs. A CD81 T
cell line was generated from an
Mtb-infected individual using
infected DCs as described in Ma-
terials and Methods. On day 11,
T cell lines were assayed by stim-
ulation with Mtb-infected DCs,
and supernatants were collected after 18–24 h. Data represents the mean
of triplicate determinations of IFN-g as determined by ELISA. In this and
subsequent experiments, the SD is ,5% of the mean.
Figure 2. Mtb-reactive CD81 CTL are found preferentially in individ-
uals infected with Mtb. Mtb-reactive T cell lines were generated and as-
sayed as described in Materials and Methods. Lines were generated from
five individuals with evidence of Mtb infection (PPD . 15 mm), and
from six individuals with no evidence of Mtb infection (PPD , 5 mm;
no history of bacillus Calmette-Guérin vaccination) in three separate ex-
periments. Stimulation index 5 (Experimental IFN-g)/(Control IFN-g).
Each tick represents 5 SI units. Positive responses are defined as SI . 5. 
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-DQ cannot explain the observed results. Although restric-
tion by HLA-DP cannot be formally excluded, it is similar
in its degree of polymorphism to HLA-DQ, making it un-
likely that a single HLA-DP allele is restricting these clones.
Lack of HLA-A, -B, -C, -DR, or -DQ restriction has been
observed from all clones tested to date, a total of seven
clones from two PPD-reactive donors. Parallel experiments
have been performed with Mtb-infected, CD1
 
2
 
 macro-
phages with similar results (data not shown). To further de-
fine the restricting allele, a variety of cell-lines, including
HL-60, U937, C1R, T2, and .221, were coincubated with
live Mtb and the CD8
 
1
 
 T cell clones. None of these cell lines
were able to process and present the antigen (data not shown).
 
Anti–MHC Class I Antibody Inhibits Recognition of Mtb-
infected DCs by CD8
 
1
 
 T Cells.
 
The addition of the MHC
class I antibody (W6/32) but not the MHC class II anti-
body (L243) or an isotype-matched control inhibited anti-
gen-induced cytokine release by 60% (2 
 
m
 
g/ml final con-
centration of antibody; Fig. 6). In a series of separate
experiments, we found a similar degree of inhibition with
W6/32 using CD8
 
1
 
 T cell clones specific for HIV p24,
and observed 
 
z
 
70% inhibition of CD4
 
1
 
 T cell clones spe-
cific for PPD with L243. In neither case was nonspecific
inhibition observed with the antibody preparations used (data
not shown). These data suggest that MHC class I–like mol-
ecules are required for the recognition of Mtb-infected DCs.
 
Antigen Presentation Requires Phagocytosis and Proteasomal
Degradation, but Does Not Require Golgi-ER Transport.
 
The failure to demonstrate HLA-A, -B, or -C restriction of
these T cell clones suggested that antigen presentation
could be occurring through a nonpolymorphic MHC Class
Ib molecule such as CD1 or HLA-E, -F or -H. To derive
insights into the cellular processes required to present Mtb
antigens to CD8
 
1
 
 T cells, inhibitors known to interfere
with discrete stages of antigen processing were used. DCs
were preincubated in the presence of inhibitor for 1 h,
pulsed overnight with Mtb in the presence of inhibitor,
and fixed in 0.1% glutaraldehyde. As shown in Fig. 7 
 
A
 
,
neither chloroquine (an inhibitor of phago-lysosomal acidi-
fication and thus MHC class II–dependent peptide presen-
tation) nor brefeldin A (which inhibits Golgi-ER transport,
and thus MHC class I–dependent peptide presentation) af-
fected the Mtb-induced generation of IFN-
 
g
 
. In contrast,
the addition of either the phagocytosis inhibitor cytochala-
sin D or the potent proteasomal inhibitor lactacystin re-
sulted in complete inhibition. Lactacystin did not appear to
Figure 3. Reciprocal specificity of Mtb-reactive and HIV gp24–reac-
tive T cells. 5 3 104 Mtb-reactive CD81 T cell clones (23 and 29) and an
HLA-B44–restricted HIV p24-specific CD81 T cells (clone 10D10-82)
were incubated with 3 3 104 DCs (autologous to clones 23 and 29; B44-
positive) that had been treated for 18 h with Mtb, HLA-B44–restricted
HIV p24 peptide 103 (303–322), or LPS (5 mg/ml). Supernatants were
collected after 18 h and assessed for the presence of IFN-g by ELISA.
Each tick represents 1000 pg/ml. These data are representative of three
experiments.
Figure 4. CD81 T cell clones
recognize M. bovis but not M.
avium.  CD81 T cell clone 23 was
stimulated with autologous DCs
infected with varying numbers of
either Mtb (H37Rv), M. bovis, or
M. avium. After 18 h, superna-
tants were collected and assessed
for the presence of IFN-g by
ELISA.
Figure 5. Mtb-specific CD81 T cells are not restricted by a unique
HLA-A, -B, or -C allele. CD81 T cell clones 23 and 29 were stimulated
with various DCs that had been Mtb infected or not (control) and fixed
with 1% paraformaldahyde before addition to culture. DCs from different
HLA-typed donors were used as indicated where D160 is autologous to
the clones tested. After 18 h, supernatants were collected and assessed for
the presence of IFN-g by ELISA. This experiment is representative of
three such experiments.
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be nonspecifically toxic to the DCs, as it did not inhibit an-
tigen presentation to an Mtb-reactive CD41 T cell clone
using the same DCs (Fig. 7 B). Moreover, both brefeldin A
and lactacystin were effective in blocking the presentation
of the influenza matrix peptide to an HLA-A2–restricted
CTL clone by influenza virus–infected DCs (Fig. 7 B). Taken
together, these data indicate that the processing and presen-
tation of Mtb antigen to these CD81 T cells requires phago-
cytosis of the bacteria, with antigen gaining entry to the cyto-
plasm where proteasomal degradation occurs. However, the
absence of inhibition by brefeldin A demonstrates that the
antigen must bypass the Golgi-ER, possibly being processed
and released into the extracellular milieu, and then presented.
Discussion
Studies in mouse models have demonstrated the impor-
tance of CD81 T lymphocytes in protective immunity to
tuberculosis. In this paper, we provide definitive evidence
that human CD81 T cells recognize protein antigens pre-
sented by Mtb-infected DCs and macrophages. The anti-
genic specificity of this response was clearly established using
a reciprocal specificity analysis with an HIV p24–reactive
CTL. Moreover, all of the healthy Mtb-infected donors
that have been tested to date have strong CD81 T cell re-
Figure 6. Anti HLA class I antibody inhibits T cell–dependent genera-
tion of IFN-g. CD81 T cell clones 23 and 29 were stimulated with Mtb-
infected or control DCs in the presence of anti–MHC class I (W6/32; 2
mg/ml), anti–MHC class II (L243; 2 mg/ml), or IgG2a isotype control
antibody (2 mg/ml), added at the beginning of the assay. After 18 h, su-
pernatants were collected and assessed for the presence of IFN-g by ELISA.
Figure 7. Effect of metabolic inhibitors on presentation of Mtb-derived
antigen. (A) CD81 T cell clones 23 and 29 were stimulated with DCs
that had been preincubated with metabolic inhibitors, lactacystin (protea-
somal degradation; 40 mM), brefeldin A (Golgi-ER transport; 10 mg/ml),
chloroquine (endosomal acidification; 100 mM), or cytochalasin D (phago-
cytosis; 10 mg/ml) for 1 h before the addition of Mtb, and subsequently
fixed in 1% paraformaldehyde after 18 h of infection. After 18 h, superna-
tants were collected and assessed for the presence of IFN-g by ELISA.
This experiment is representative of three such experiments. (B) An influ-
enza matrix peptide–reactive CTL clone was stimulated with DCs that
had been preincubated with metabolic inhibitors lactacystin or brefeldin
A for 1 h before the addition of live influenza A virus and fixed after 18 h
of infection. In the second graph, a PPD-reactive CD41 T cell clone was
stimulated with the APCs described in A. After 18 h, supernatants were
collected and assessed for the presence of IFN-g by ELISA. This experi-
ment is representative of two such experiments.1638 Human CD81 T Cells to Mycobacterium tuberculosis
sponses to Mtb-infected DCs, whereas only two out of six
of those who are not Mtb infected have shown responses,
indicating the recall nature of these responses and suggest-
ing the importance of CD81 T cells in protective immu-
nity. Furthermore, activation of T cell clones is dependent
on the presence of Mtb and APCs. Finally, the T cell
clones respond to Mtb and the closely related pathogenic
M. bovis, but not to M. avium.
The presentation of Mtb antigen to CD81 T cell clones
was inhibited by the W6/32 antibody, suggesting that the
T cell recognizes antigen in the context of MHC class I.
However, attempts to identify a specific HLA-A–, -B–, or
-C–restricting allele were unsuccessful. Because the W6/32
antibody inhibits both classical and nonclassical MHC class
I molecules such as HLA-E, -F, or -H, it is possible that the
antigen is presented by such a nonpolymorphic MHC class
Ib molecule (23, 24). Our data suggest that CD1a, -b, or -c
are not required based on the ability of cells lacking these
markers to present Mtb-derived antigen. The expression
and function of CD1d and -e remain unclear, leaving re-
striction by this molecule a possibility. Unfortunately, a va-
riety of cell lines were not able to process and present anti-
gen derived from live Mtb, precluding the use of this
approach to further define the restricting allele.
Metabolic inhibition was used to further define the
mode of antigen processing, in particular with regard to the
requirements for proteasomal processing (lactacystin),
Golgi-ER transport (brefeldin A), phagocytosis (cytochala-
sin D), and endosomal acidification (chloroquine). Both
cytochalasin D and lactacystin proved potent inhibitors of
antigen presentation, while neither chloroquine nor brefel-
din A were inhibitory. These data suggest that Mtb is
phagocytosed, with Mtb-derived proteins gaining access to
the cytosol where proteasomal degradation occurs. The
failure of brefeldin A to inhibit antigen presentation sug-
gests that proteasomally derived peptide does not require
Golgi-ER transport and thus that the antigen presenting
structure is not transported to the cell surface by the same
pathway as conventional MHC class I. The precise mecha-
nism by which such presentation occurs is unclear. Perhaps
dying cells release peptides that are presented by adjacent
live cells (paracrine processing).
The results presented here describe a processing pathway
that is distinct from conventional MHC class I or II pathways.
Exogenous particulate antigens have been reported to gain
access to the class I processing pathways (18). However, in
this model, processing and presentation requires both pha-
gocytosis and Golgi-ER transport. In contrast, Pfeiffer et al.
demonstrated that ova-peptide expressed in either E. coli or
Salmonella as a fusion protein was presented to MHC class
I–restricted T cells in a manner that was inhibited by chlo-
roquine. Of particular interest, those studies demonstrated
the presence of peptide in the extracellular milieu (19).
The simplest explanation of our data is that the processed
peptide binds a nonpolymorphic antigen-presenting struc-
ture on the cell surface, perhaps on the MHC class Ib mol-
ecules such as HLA-E, -F, or -H. In bacterial infection,
precedent for MHC class Ib–restricted antigen presentation
exists in two model systems. CD4/CD8 double negative
cytolytic T cells that are restricted by monomorphic, b2
microglobulin–associated CD1b and CD1c molecules (25,
26) have been described. These cells recognize both my-
colic acid (27) and glycolipid antigens (25). Those antigens
are processed by a novel chloroquine-sensitive, but HLA-
DM–independent mechanism (26). The CD81 CTLs de-
scribed in this paper are not CD1 restricted, in that they
recognize a proteasome-dependent antigen presented by
CD1-negative Mtb-infected macrophages.
In the mouse, the monomorphic, b2 microglobulin–
associated H2-M3 molecule has been demonstrated to
present short formylated peptides derived from Listeria
monocytogenes (28–30). Although there is no known human
homologue for H2-M3, monomorphic members of the
HLA family such as HLA-E, -F, or -H may be capable of
presentation of mycobacterially derived peptide(s).
An alternative interpretation of these data would be the
presentation of antigen by HLA class I or II structures in an
unconventional manner. For example, the T cells could
recognize peptide that binds to multiple HLA class I or II
alleles. Such promiscuous presentation has been described
for HLA-DR (31), and recently within members of the
HLA-A3 superfamily (32). However, the antibody-block-
ing data does not suggest a direct role for HLA class II mol-
ecules. Moreover, although the inhibition observed with
the anti–class I antibody W6/32 would be consistent with
restriction by MHC-Ia, the APCs tested do not fall within
a known HLA class Ia superfamily. However, it is possible
that an as yet undescribed super-family might exist. Simi-
larly, it is conceivable that antigen presentation is occurring
in a manner analogous to that of a superantigen. Although
this has been described in Mtb (33), there is no precedent
for a superantigen that requires proteasomal processing.
In short term cytolysis assays, we observed z20% spe-
cific lysis of Mtb-pulsed cells (data not shown). The rela-
tively modest cytolysis may reflect a small subset of DCs that
are sufficiently infected to present antigen, or a low abundance
of antigen. In this regard, there is a paucity of published
data regarding the ability of mouse MHC class Ia–restricted
CTLs against defined antigens to lyse Mtb-infected cells.
Recently, Zhu et al. described murine CD81 CTL to the
38-kD antigen (8). Epitope mapping revealed that CTLs
derived from DNA vaccination recognized entirely distinct
peptides than did those derived from natural infection.
In summary, we have defined a novel antigen-processing
pathway by which human CD81 T cells recognize Mtb-
infected DCs and macrophages. The antigen is presented in
a manner that is not restricted by a specific HLA-A, -B, or
-C allele. To date, all of the CD81 T cell clones we have
generated (seven clones from two donors) have the same
characteristic lack of HLA-A, -B, or -C restriction. Our
data indicate that Mtb-derived antigen is processed by the
proteasome and thus must gain access to the cytosol. Con-
sequently, further definition of the restricting element and
the antigen it presents may yield valuable insights into the
mechanism by which CD81 CTLs contribute to host de-
fense against Mtb.1639 Lewinsohn et al.
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